Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insulin in humans. 2000

M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
Department of Endocrinology and Metabolism, Eberhard Karls Universität, Tubingen, Germany. michael.stumvoll@med.uni-tuebingen.de

In addition to sc and visceral fat deposits, muscle has been shown to contain relevant amounts of lipids whose breakdown is subject to hormonal regulation. The aim of the present study was to determine insulin dose-response characteristics of systemic, sc adipose tissue and muscle lipolysis in humans. We used a combination of isotopic (primed continuous infusion of [d5]glycerol) and microdialysis techniques (catheters placed in the anterior tibial muscle and sc abdominal adipose tissue) during a three-step hyperinsulinemic-euglycemic clamp (insulin infusion, 0.1, 0.25, 1.0 mU/kg x min) in 13 lean, healthy volunteers. The glycerol rate of appearance was used as the index for systemic lipolysis; interstitial glycerol concentrations were used as the index for muscle and sc adipose tissue lipolysis. The insulin concentrations resulting in a half-maximal suppression (EC50) of systemic lipolysis, adipose tissue, and muscle lipolysis were 51, 68, and 44 pmol/L, respectively (between one another, P < 0.001). For each compartment there were significant correlations between the EC50 and the insulin sensitivity index for glucose disposal (r > 0.67; P < 0.05). However, lipolysis (as percent of baseline) was similar during the first two insulin infusion steps, but was significantly lower in adipose (22+/-2%) than in muscle (53+/-4%; P < 0.001) during step 3. Although we have no direct measurement of interstitial insulin concentrations, we conclude that based on the EC50 values, muscle is more sensitive with respect to the net effect of circulating insulin (transendothelial transport plus intracellular action) on lipolysis than sc adipose tissue in terms of exerting its full suppression within the physiological insulin range. This could be important in muscle for switching from preferential utilization of free fatty acids to glucose in the postprandial state. Inadequate suppression of im lipolysis resulting in excessive local availability of free fatty acids may represent a novel mechanism contributing to the pathogenesis of impaired glucose disposal, i.e. insulin resistance, in muscle.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008066 Lipolysis The metabolic process of breaking down LIPIDS to release FREE FATTY ACIDS, the major oxidative fuel for the body. Lipolysis may involve dietary lipids in the DIGESTIVE TRACT, circulating lipids in the BLOOD, and stored lipids in the ADIPOSE TISSUE or the LIVER. A number of enzymes are involved in such lipid hydrolysis, such as LIPASE and LIPOPROTEIN LIPASE from various tissues. Lipolyses
D008297 Male Males
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D005260 Female Females
D005990 Glycerol A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, or sweetening agent. 1,2,3-Propanetriol,Glycerin,1,2,3-Trihydroxypropane,Glycerine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
December 2007, Metabolism: clinical and experimental,
M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
February 2014, The Journal of clinical endocrinology and metabolism,
M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
May 1973, Acta medica Scandinavica,
M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
September 2005, American journal of physiology. Endocrinology and metabolism,
M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
February 2007, American journal of physiology. Endocrinology and metabolism,
M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
July 2014, Diabetes, obesity & metabolism,
M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
December 1999, European journal of clinical investigation,
M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
December 2019, Diabetes,
M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
May 2000, Molecular genetics and metabolism,
M Stumvoll, and S Jacob, and H G Wahl, and B Hauer, and K Löblein, and P Grauer, and R Becker, and M Nielsen, and W Renn, and H Häring
October 2013, American journal of physiology. Endocrinology and metabolism,
Copied contents to your clipboard!